Cancer
Drugs for Breakthrough Pain, Including Therapies From Cephalon and Zars Pharma, Will Drive Growth in the Cancer Pain Market
Published in Clinical Oncology Week, May 7th, 2007
Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that growth in the cancer pain market through 2015 will be driven by the launch of several novel reformulations of drugs in the breakthrough pain segment, including therapies from Cephalon and Zars Pharma. Breakthrough pain is characterized by severe flares of pain that occur despite treatment with medication to control chronic pain.
The new Pharmacor report Cancer Pain finds that the launch of Cephalon's Fentora and Cephalon/Zars' Titragesia will drive the market to treat breakthrough pain. In 2015, expensive novel formulations of fentanyl such as...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Clinical Oncology Week
More Articles from Clinical Oncology Week
- Breast Cancer
Neither abortion nor miscarriage associated with breast cancer risk - Cancer
Patients with rare brain tumor may have genetic predisposition - Colon Cancer
Social factors not genetics drive racial disparities in colorectal cancer survival - Colon Cancer
Study calls virtual colonoscopy most cost-effective colon cancer screening test - Leukemia
Antioxidant found in many foods and red wine is potent and selective killer of leukemia cells - Leukemia
Knocking Out Survival Protein Could Aid Leukemia Treatment - More from this issue of Clinical Oncology Week
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
